Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Trial Details
- NCT ID
- NCT07249905
- Phase
- PHASE1 / PHASE2
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Richmond, Victoria, Australia|-37.81819,145.00176
- Nedlands, Western Australia, Australia|-31.98184,115.8073
Key Eligibility Criteria
- Participant must be ≥ 18 years of age.
- Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma \[HGBCL\], primary mediastinal B-cell l…
- Participant has relapsed or progressed on at least 2 prior lines of therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →